Patients with inflammatory bowel disease had a similar risk for and outcomes from coronavirus disease 2019 as those in the general population.
Vitamin D may be used to reduce the risk of immune checkpoint inhibitor-related colitis, as well as ulcerative colitis and graft-vs-host disease.
The majority of endoscopic modalities for ulcerative colitis (UC) neoplasia surveillance were similarly effective, but white light standard definition (WL SD) was the least so.
Researchers evaluated the association of psoriasis and psoriatic arthritis with inflammatory bowel disease and other gastrointestinal illnesses.
Probiotics should only be recommended for specific patient populations since there is not enough evidence to support their use in the majority of digestive conditions, according to new clinical guidelines released by the American Gastroenterological Association (AGA) and recently published in Gastroenterology.
According to results from a large cohort validation study, IBD-Disk was reported to be both viable and reliable.
Researchers assessed the microbial profiles of patients with IBD with recurrent C. difficile infection.
Measurement of fecal volatile organic compounds (VOC) was effective in identifying inflammatory bowel disease (IBD) biomarkers, but not for monitoring disease activity.
Certain enteric pathogens are associated with higher risk of incident inflammatory bowel disease, while others are could be protective.
At week 10, filgotinib 200mg met the primary end point with a significantly higher proportion of patients achieving clinical remission compared with placebo.
The total lifetime risk for colorectal cancer (CRC) in patients with ulcerative colitis (UC) was comparable to that observed in the general population.
Patients with acute severe ulcerative colitis (ASUC) who responded to intravenous steroids (IVS) had a low rate of colectomy over 5 years of follow-up.
Baseline infliximab clearance is a strong predictive factor for colectomy in hospitalized patients with acute severe UC receiving salvage therapy.
Ustekinumab treatment of moderate-to-severe ulcerative colitis (UC) was effective for some patients, according to recent research.
It is thought that dysregulation of the gut microbiome could cause increased production of pro-inflammatory toxins that can predispose patients to the development of UC.
Segmental histologic normalization did not improve clinical outcomes of ulcerative colitis.
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios can be used to predict mucosal healing in patients with ulcerative colitis treated with anti-TNF in monotherapy.
Older age is associated with an increased risk for bacteremia in hospitalized patients with inflammatory bowel disease.
Clinical remission was more likely with vedolizumab vs infliximab in UC after failure of initial anti-TNF agent.
Researchers evaluated the efficacy and safety of etrasimod, an oral, selective sphingosine 1-phosphate receptor modulator in development for immune-mediated inflammatory disorders, in patients with moderate to severe ulcerative colitis.